IQVIA Holdings Inc. (IQV) Return on Equity (ROE): 22.26%
Is IQVIA Holdings Inc.’s return on equity (ROE) high or low?
IQVIA Holdings Inc.'s return on equity (ROE) of 22.26% is 27% above its 5-year average of 17.55%, near the high end of its 5-year range (4.65%–22.63%).
The return on equity (ROE) for IQVIA Holdings Inc. (IQV) is 22.26% as of Wednesday, June 10, 2026. It is above its 12-month average by 2.25% (21.77%).
IQV Return on Equity (ROE) Chart
IQV Average Return on Equity (ROE) Chart
IQV Current vs Average Return on Equity (ROE) Chart
IQV Return on Equity (ROE) Metrics
RETURN ON EQUITY (ROE)
22.26%
RETURN ON EQUITY (ROE) AVG TTM
21.77%
RETURN ON EQUITY (ROE) AVG 3Y
21.17%
RETURN ON EQUITY (ROE) AVG 5Y
17.55%
RETURN ON EQUITY (ROE) AVG 10Y
1.32%
RETURN ON EQUITY (ROE) AVG 15Y
-6.75%
RETURN ON EQUITY (ROE) AVG 20Y
-6.75%
CURRENT VS TTM AVG
+2.25%
CURRENT VS 3Y AVG
+5.15%
CURRENT VS 5Y AVG
+26.81%
CURRENT VS 10Y AVG
+1591.02%
CURRENT VS 15Y AVG
+429.56%
CURRENT VS 20Y AVG
+429.56%
IQV Competitors' Return on Equity (ROE)
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IQVIA Holdings Inc. (IQV) | $30.60B | 22.26% | 21.77% | 21.17% | 17.55% |
| Medline Inc. (MDLN) | $30.90B | 8.55% | 9.02% | 4.86% | 4.86% |
| Centene Corporation (CNC) | $31.94B | -30.07% | -10.46% | -1.37% | 1.10% |
| DexCom, Inc. (DXCM) | $29.24B | 31.47% | 28.93% | 25.01% | 22.95% |
| Biogen Inc. (BIIB) | $29.00B | 7.36% | 8.42% | 11.86% | 16.52% |
| Zoetis Inc. (ZTS) | $34.20B | 81.75% | 66.19% | 56.82% | 52.60% |
| Veeva Systems Inc. (VEEV) | $26.73B | 12.89% | 12.42% | 12.32% | 13.45% |
| Agilent Technologies, Inc. (A) | $37.17B | 19.85% | 20.59% | 21.51% | 20.54% |
| Waters Corporation (WAT) | $23.83B | 2.94% | 29.98% | 64.02% | 111.55% |
| Mettler-Toledo International Inc. (MTD) | $22.85B | -3677.41% | -2178.82% | -341.14% | -117.12% |
Return Analysis
ROE
22.3%
ROA
4.7%
IQVIA Holdings Inc. Return on Equity (ROE) Formula & Definition
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
IQVIA Holdings Inc. Return on Equity (ROE) FAQ
- What is the return on equity (ROE) for IQVIA Holdings Inc. (IQV)?
- The return on equity (ROE) for IQV stock is 22.26%.
- Is IQVIA Holdings Inc.'s return on equity (ROE) high or low?
- IQVIA Holdings Inc.'s return on equity (ROE) of 22.26% is 27% above its 5-year average of 17.55%, near the high end of its 5-year range (4.65%–22.63%).
- What is the TTM average return on equity (ROE) for IQVIA Holdings Inc. (IQV)?
- The TTM average return on equity (ROE) for IQV stock is 21.77%.
- What is the 3Y average return on equity (ROE) for IQVIA Holdings Inc. (IQV)?
- The 3Y average return on equity (ROE) for IQV stock is 21.17%.
- What is the 5Y average return on equity (ROE) for IQVIA Holdings Inc. (IQV)?
- The 5Y average return on equity (ROE) for IQV stock is 17.55%.
- What is the 10Y average return on equity (ROE) for IQVIA Holdings Inc. (IQV)?
- The 10Y average return on equity (ROE) for IQV stock is 1.32%.
- What is the 15Y average return on equity (ROE) for IQVIA Holdings Inc. (IQV)?
- The 15Y average return on equity (ROE) for IQV stock is -6.75%.
- What is the 20Y average return on equity (ROE) for IQVIA Holdings Inc. (IQV)?
- The 20Y average return on equity (ROE) for IQV stock is -6.75%.
IQVIA Holdings Inc. Return on Equity (ROE) History
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 20.91% |
| 2024-12-31 | 22.63% |
| 2023-12-31 | 22.22% |
| 2022-12-31 | 18.92% |
| 2021-12-31 | 15.99% |
| 2020-12-31 | 4.65% |
| 2019-12-31 | 3.18% |
| 2018-12-31 | 3.86% |
| 2017-12-31 | 16.14% |
| 2016-12-31 | 1.33% |
| 2015-12-31 | -115.35% |
| 2014-12-31 | -50.62% |
| 2013-12-31 | -33.95% |
| 2012-12-31 | -13.06% |
| 2011-12-31 | -24.92% |
| 2010-12-31 | 0.00% |
Related Metrics
About IQVIA Holdings Inc.
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Ari Bousbib